20102020 Apsis Therapeutics, Ltd. All rights reserved.

Cas9-lgRNATM technology is developed based on recent breakthroughs in gene editing biotechnology (CRISPR-Cas9) for treatments of chronic or latent viral infections by eliminating the viral genetic materials of latently integrated (proviral DNA) or non-replicating episomal viral genomes (such as cccDNA) in human cells.

 

lgRNAs composed of chemically ligated modules enable chemical modifications essential for efficacy, specificity, and stability, and for targeted delivery.

 

This chemical ligation strategy provides diverse chemically modified lgRNAs targeting multiple sites and/or variants/mutations of a single site in viral genomes equivalent to combination therapies such as HAART, and fragmentizing viral DNAs to avoid resistance mutations introduced by NHEJ at the target sites.